992 related articles for article (PubMed ID: 25410866)
21. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
22. Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.
Hau PM; Deng W; Jia L; Yang J; Tsurumi T; Chiang AK; Huen MS; Tsao SW
J Virol; 2015 Jan; 89(1):652-68. PubMed ID: 25355892
[TBL] [Abstract][Full Text] [Related]
23. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
24. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
[TBL] [Abstract][Full Text] [Related]
26. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
Jung YJ; Choi H; Kim H; Lee SK
J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
[TBL] [Abstract][Full Text] [Related]
28. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
[TBL] [Abstract][Full Text] [Related]
29. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
30. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis.
Kim H; Choi H; Lee SK
J Virol; 2016 Feb; 90(3):1359-68. PubMed ID: 26581978
[TBL] [Abstract][Full Text] [Related]
32. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D.
Bhende PM; Dickerson SJ; Sun X; Feng WH; Kenney SC
J Virol; 2007 Jul; 81(14):7363-70. PubMed ID: 17494074
[TBL] [Abstract][Full Text] [Related]
33. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
34. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.
Iempridee T; Reusch JA; Riching A; Johannsen EC; Dovat S; Kenney SC; Mertz JE
J Virol; 2014 May; 88(9):4811-27. PubMed ID: 24522918
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes.
Chen YJ; Chen YL; Chang Y; Wu CC; Ko YC; Tsao SW; Chen JY; Lin SF
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490592
[TBL] [Abstract][Full Text] [Related]
37. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase.
Liu X; Cohen JI
J Virol; 2016 Jan; 90(2):1129-38. PubMed ID: 26559845
[TBL] [Abstract][Full Text] [Related]
39. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
40. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
Bristol JA; Djavadian R; Albright ER; Coleman CB; Ohashi M; Hayes M; Romero-Masters JC; Barlow EA; Farrell PJ; Rochford R; Kalejta RF; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Jul; 14(7):e1007179. PubMed ID: 30052684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]